Dyax Corp. is a fully integrated biopharmaceutical company engaged in developing and commercializing novel biotherapeutics for unmet medical needs. Ecallantide, the company’s lead product, has been approved in the U.S. under the brand name KALBITOR for treating acute attacks of hereditary angioedema (HAE) in patients 16 and older. The company is commercializing KALBITOR in the U.S. independently and establishing strategic collaborations to develop and commercialize ecallantide for treating HAE in key regions throughout the world. For more information, visit the company’s Web site at www.dyax.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: